Digital Transformation of Monoclonal Antibody Characterization Analytical Workflows

Importance of the Topic

This study addresses the growing need for fully digitalized analytical workflows in biopharmaceutical quality control laboratories. Monoclonal antibody (mAb) products require rigorous testing for aggregation and charge variants as critical quality attributes. By integrating laboratory information management and chromatography data systems in a cloud-based environment, this approach aims to reduce manual errors, streamline sample handling, and accelerate decision making.

Objectives and Overview of the Study

The primary goals of this work were to:

• Emulate a small-scale mAb QC laboratory for release testing of aggregation and charge variants
• Implement paperless workflows from sample submission to data archiving
• Demonstrate seamless integration between SLIMS and OpenLab CDS in a cloud infrastructure
• Assess the impact of digitalization on operational efficiency and data integrity

Methodology and Instrumentation

A biopharmaceutical QC environment was configured using two Agilent 1290 Infinity II LC setups: one for aggregation analysis and one for charge variant profiling. Samples from two mAb production batches were registered in SLIMS, capturing metadata such as volume, storage location, and lot number. SLIMS managed reagent inventories and expiration dates, triggering alerts before resource depletion.

• Agilent 1290 Infinity II bio high-speed and flexible pumps
• Agilent 1290 Infinity II multisampler with cooling option
• Multicolumn thermostats with bio heat exchangers
• Diode array detectors for spectral detection
• SLIMS 6.9 and OpenLab CDS client/server 2.7 with Sample Scheduler
• Microsoft Azure cloud servers hosting SLIMS and OpenLab CDS

Mobile phases were phosphate buffer–based and prepared via visualized SLIMS protocols, which automatically updated chemical inventories and guided technicians step by step.

Results and Discussion

Two mAb samples underwent both aggregation and charge variant analyses in a unified workflow. Analytical requests and instrument methods were launched directly from SLIMS, eliminating manual data entry into OpenLab CDS. Acquisition run records included sample metadata, column and mobile phase details, and result summaries. Automated evaluation rules flagged one sample for acidic and basic variant out-of-specification results, illustrating timely quality alerts.

Benefits and Practical Applications

The integrated solution delivered several advantages:

• Reduced manual transcription and associated errors
• Real-time inventory and resource management
• Centralized tracking of sample metadata and results
• Accelerated turnaround time from request to final report

This digital transformation supports compliance with regulatory guidelines while enhancing laboratory throughput.

Future Trends and Opportunities

Advances in cloud computing and AI-driven data analysis will further optimize biopharma QC workflows. Future developments may include:

• Predictive maintenance of instruments based on usage data
• AI-assisted anomaly detection in chromatographic data
• Expanded integration with enterprise ERP and manufacturing execution systems
• Standardized digital protocols for cross-site comparability

Conclusion

This case study demonstrates a fully digitalized mAb QC workflow that spans sample registration, mobile phase preparation, data acquisition, and automated result evaluation. The seamless integration of SLIMS and OpenLab CDS in a cloud environment enhances data integrity, operational efficiency, and regulatory compliance.

Reference

1. Facts About the Current Good Manufacturing Practices (CGMP).
2. ICH Harmonized Tripartite Guideline Specifications: Test Procedures and Acceptance Criteria for Biotechnological/Biological Products Q6B.
3. Bian Y. Charge Variant and Aggregation Analysis of Innovator and Biosimilars of Rituximab. Agilent Technologies application note 5994-1496EN, 2019.